On October 24, 2024, DENTSPLY issued a press release "announc[ing] the voluntary suspension of sales and marketing of its Byte Aligners and Impression Kits while the Company conducts a review of certain regulatory requirements related to these products," and that its "decision was made in consultation with the U.S. Food and Drug Administration (FDA)." On this news, DENTSPLY’s stock price fell $1.10 per share, or 4.51%, to close at $23.31 per share on October 25, 2024.
If you have any questions or would like to discuss this investigation, please contact Kessler Topaz Meltzer & Check, LLP: Jonathan Naji, Esq. (484) 270-1453 or via e-mail at info@ktmc.com.